Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination
•Inactivated influenza A/H7N7 vaccine results in development of memory responses.•Cross-reactive antibodies develop post heterologous influenza A/H7 prime-boost.•The inclusion of an AS03 adjuvant results in broadly cross-reactive antibodies. Influenza A/H7N9 viruses are undergoing antigenic drift si...
Saved in:
Published in | Vaccine Vol. 37; no. 19; pp. 2561 - 2568 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
01.05.2019
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •Inactivated influenza A/H7N7 vaccine results in development of memory responses.•Cross-reactive antibodies develop post heterologous influenza A/H7 prime-boost.•The inclusion of an AS03 adjuvant results in broadly cross-reactive antibodies.
Influenza A/H7N9 viruses are undergoing antigenic drift since their emergence in 2013, and vaccination strategies are needed for pandemic preparedness. Two doses of adjuvanted monovalent inactivated influenza A/H7N9 vaccine (IIV1 A/H7N9) are needed for optimal serological responses. However, administering 2 doses in a pandemic setting might be challenging. We evaluated the immunogenicity of “boosting” with IIV1 A/H7N9 in subjects “primed” 8 years previously with IIV1 A/H7N7.
We administered 1 booster dose containing 45 mcg of IIV1 A/H7N9 hemagglutinin to 17 recipients of 2 prior doses of IIV1 A/H7N7, and to 10 influenza A/H7-naïve subjects. We tested their post-boosting sera for antibodies (Ab) against homologous influenza A/H7N9 using a hemagglutination inhibition assay; and compared their Ab titers to those in stored sera from recipients of AS03-adjuvanted IIV1 A/H7N9 against 9 strains of influenza A/H7N9 viruses.
The percentage of subjects with Ab titers ≥40 on Days 9 and 29 post boosting, respectively, was 65% and 41% in primed subjects and 10% and 0% in unprimed subjects. The Ab titers in recipients of AS03-adjuvanted IIV1 A/H7N9 were higher than those in the prime-boost group against a panel of influenza A/H7N9 viruses, except for 2 highly pathogenic strains.
Priming with IIV1 A/H7 results in serological responses following a delayed boost with 1 dose of unadjuvanted IIV1 A/H7N9, despite lack of antibody response after the prime. Optimizing prime-boost approaches would benefit pandemic preparedness.
ClinicalTrials.gov identifier: NCT02586792. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2019.03.071 |